Overview

Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia

Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
A Non-randomized, prospective , multicenter, open uncontrolled study in patients with acute myelogenous (AML) or lymphoblastic leukaemia (ALL)
Phase:
Phase 2
Details
Lead Sponsor:
Matinas BioPharma Nanotechnologies, Inc.
Collaborators:
The Clinical Trials Centre Cologne
University of Cologne
Treatments:
Amphotericin B
Antifungal Agents
Liposomal amphotericin B
Miconazole